Study tracks Real-Life results for painful skin condition treatment

NCT ID NCT07282015

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing how well the drug secukinumab works for Canadian adults with moderate-to-severe hidradenitis suppurativa (HS) during their regular medical care. It will track 142 patients for a year to see if their disease severity improves and monitor the drug's safety. The goal is to understand real-world treatment outcomes, not to test a new cure.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Winnipeg, Manitoba, R3M 3Z4, Canada
Novartis Investigative Site
RECRUITING

Hamilton, Ontario, L8P4B4, Canada
Novartis Investigative Site
RECRUITING

Markham, Ontario, L3P 1X3, Canada
Novartis Investigative Site
RECRUITING

Mississauga, Ontario, L4W 0C2, Canada
Novartis Investigative Site
RECRUITING

Richmond Hill, Ontario, L4C 9M7, Canada
Novartis Investigative Site
RECRUITING

Waterloo, Ontario, N2J 1C4, Canada
Novartis Investigative Site
RECRUITING

Sherbrooke, Quebec, J1L 0H8, Canada

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA